低剂量冠脉内阿替普酶对急性心梗微血管阻塞的影响
这项随机临床试验纳入440例症状发作6小时内的急性STEMI患者,在直接PCI再灌注后、支架植入前给予安慰剂、阿替普酶10 mg或20 mg冠脉内注射。结果显示,20 mg组与安慰剂组的微血管阻塞程度无显著差异,10 mg组同样无差异,主要不良心脏事件三组相近;研究因无效性提前终止,不支持该治疗策略。
要点
- STEMI直接PCI期间冠脉内低剂量阿替普酶未减少微血管阻塞。
- 研究因预设无效性标准提前终止,不支持该辅助治疗。
核心结论
- 在症状发作6小时内就诊的急性STEMI患者中,直接PCI期间给予冠脉内低剂量阿替普酶未减少微血管阻塞,研究结果不支持该治疗。
研究设计与样本
- 研究为1:1:1剂量探索随机临床试验,2016年3月17日至2017年12月21日在英国11家医院纳入440例急性STEMI患者。
- 患者随机接受安慰剂(n=151)、阿替普酶10 mg(n=144)或阿替普酶20 mg(n=145),于直接PCI再灌注后、支架植入前经手动输注5至10分钟给药。
- 主要终点为入组后第2至7天心脏磁共振显示的微血管阻塞占左心室质量百分比,主要比较为20 mg组与安慰剂组。
主要发现
- 主要不良心脏事件(心源性死亡、非致死性心梗、心衰非计划住院)在安慰剂组为15例(10.1%)、10 mg组18例(12.9%)、20 mg组12例(8.2%)。
- 基于前267例随机患者的预设分析,两个治疗组主要终点条件把握度均低于30%(无效性标准),研究于2017年12月21日停止招募。
关键数值与推荐
- 主要终点在396例患者(90%)中达成,17例(3.9%)退出,其余随访至3个月。
- 患者平均年龄60.5岁,女性占15%。
临床怎么用
- 对于症状发作6小时内接受直接PCI的急性STEMI患者,不建议常规经冠脉给予低剂量阿替普酶以减少微血管阻塞。
局限性
- 研究因无效性提前终止,样本量未达到原计划,可能影响把握度。
- 主要终点仅在90%随机患者中达成,随访至3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Microvascular obstruction commonly affects patients with acute ST-segment elevation myocardial infarction (STEMI) and is associated with adverse outcomes. OBJECTIVE: To determine whether a therapeutic strategy involving low-dose intracoronary fibrinolytic therapy with alteplase infused early after coronary reperfusion will reduce microvascular obstruction. DESIGN, SETTING, AND PARTICIPANTS: Between March 17, 2016, and December 21, 2017, 440 patients presenting at 11 hospitals in the United Kingdom within 6 hours of STEMI due to a proximal-mid-vessel occlusion of a major coronary artery were randomized in a 1:1:1 dose-ranging trial design. Patient follow-up to 3 months was completed on April 12, 2018. INTERVENTIONS: Participants were randomly assigned to treatment with placebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145) by manual infusion over 5 to 10 minutes. The intervention was scheduled to occur early during the primary PCI procedure, after reperfusion of the infarct-related coronary artery and before stent implant. MAIN OUTCOMES AND MEASURES: The primary outcome was the amount of microvascular obstruction (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MRI) conducted from days 2 through 7 after enrollment. The primary comparison was the alteplase 20-mg group vs the placebo group; if not significant, the alteplase 10-mg group vs the placebo group was considered a secondary analysis. RESULTS: Recruitment stopped on December 21, 2017, because conditional power for the primary outcome based on a prespecified analysis of the first 267 randomized participants was less than 30% in both treatment groups (futility criterion). Among the 440 patients randomized (mean age, 60.5 years; 15% women), the primary end point was achieved in 396 patients (90%), 17 (3.9%) withdrew, and all others were followed up to 3 months. In the primary analysis, the mean microvascular obstruction did not differ between the 20-mg alteplase and placebo groups (3.5% vs 2.3%; estimated difference, 1.16%; 95% CI, -0.08% to 2.41%; P = .32) nor in the analysis of 10-mg alteplase vs placebo groups (2.6% vs 2.3%; estimated difference, 0.29%; 95% CI, -0.76% to 1.35%; P = .74). Major adverse cardiac events (cardiac death, nonfatal MI, unplanned hospitalization for heart failure) occurred in 15 patients (10.1%) in the placebo group, 18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%) in the 20-mg alteplase group. CONCLUSIONS AND RELEVANCE: Among patients with acute STEMI presenting within 6 hours of symptoms, adjunctive low-dose intracoronary alteplase given during the primary percutaneous intervention did not reduce microvascular obstruction. The study findings do not support this treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02257294.
引用
- McCartney PJ, Eteiba H, Maznyczka AM, et al. Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2019. PMID: 30620371. doi:10.1001/jama.2018.19802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。